GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PharmaResearch Co Ltd (XKRX:214450) » Definitions » Cyclically Adjusted FCF per Share

PharmaResearch Co (XKRX:214450) Cyclically Adjusted FCF per Share : ₩2,667.78 (As of Mar. 2025)


View and export this data going back to 2015. Start your Free Trial

What is PharmaResearch Co Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

PharmaResearch Co's adjusted free cash flow per share for the three months ended in Mar. 2025 was ₩1,864.086. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is ₩2,667.78 for the trailing ten years ended in Mar. 2025.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2025-07-24), PharmaResearch Co's current stock price is ₩583000.00. PharmaResearch Co's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 was ₩2,667.78. PharmaResearch Co's Cyclically Adjusted Price-to-FCF of today is 218.53.

During the past 11 years, the highest Cyclically Adjusted Price-to-FCF of PharmaResearch Co was 214.41. The lowest was 63.31. And the median was 104.67.


PharmaResearch Co Cyclically Adjusted FCF per Share Historical Data

The historical data trend for PharmaResearch Co's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PharmaResearch Co Cyclically Adjusted FCF per Share Chart

PharmaResearch Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 2,529.58

PharmaResearch Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 2,100.84 2,328.81 2,529.58 2,667.78

Competitive Comparison of PharmaResearch Co's Cyclically Adjusted FCF per Share

For the Biotechnology subindustry, PharmaResearch Co's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PharmaResearch Co's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PharmaResearch Co's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where PharmaResearch Co's Cyclically Adjusted Price-to-FCF falls into.


;
;

PharmaResearch Co Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, PharmaResearch Co's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=1864.086/122.5900*122.5900
=1,864.086

Current CPI (Mar. 2025) = 122.5900.

PharmaResearch Co Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201506 633.255 100.051 775.914
201509 545.691 100.111 668.222
201512 303.253 100.220 370.940
201603 247.338 100.561 301.520
201606 23.033 100.791 28.015
201609 145.326 101.461 175.589
201612 242.260 101.561 292.421
201703 214.960 102.851 256.216
201706 85.801 102.611 102.507
201709 -213.283 103.491 -252.645
201712 90.395 102.991 107.597
201803 -907.656 104.101 -1,068.864
201806 -431.614 104.130 -508.128
201809 -745.924 105.651 -865.522
201812 -529.437 104.351 -621.976
201903 -138.445 104.491 -162.425
201906 530.784 104.881 620.407
201909 189.232 105.200 220.512
201912 426.386 105.121 497.241
202003 83.421 105.354 97.069
202006 763.350 105.112 890.281
202009 -994.759 106.198 -1,148.308
202012 -171.005 105.765 -198.208
202103 1,011.614 107.357 1,155.151
202106 841.854 107.579 959.325
202109 1,258.575 108.759 1,418.627
202112 1,017.147 109.676 1,136.909
202203 634.305 111.848 695.224
202206 1,209.637 114.072 1,299.960
202209 1,379.761 114.715 1,474.476
202212 930.762 115.179 990.649
202303 1,064.221 116.507 1,119.782
202306 914.628 117.182 956.838
202309 1,153.015 118.964 1,188.163
202312 1,934.620 118.837 1,995.716
202403 3,020.990 120.123 3,083.028
202406 1,480.978 120.007 1,512.850
202409 2,659.123 120.861 2,697.159
202412 2,521.172 121.135 2,551.451
202503 1,864.086 122.590 1,864.086

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


PharmaResearch Co  (XKRX:214450) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

PharmaResearch Co's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=583000.00/2667.78
=218.53

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 11 years, the highest Cyclically Adjusted Price-to-FCF of PharmaResearch Co was 214.41. The lowest was 63.31. And the median was 104.67.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


PharmaResearch Co Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of PharmaResearch Co's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


PharmaResearch Co Business Description

Industry
Traded in Other Exchanges
N/A
Address
74 Pangyo-ro 255beon-gil, Bundang-gu, Gyeonggi-do, Seongnam, KOR, 463-400
PharmaResearch Co Ltd formerly Pharma Research Products Co Ltd is a bio pharmaceutical firm which realizes a new treatment paradigm for regenerative medicine. Its products include Rejuran, Rejuvenex, and Re-An eye drops. It also provides medical devices, cosme ceuticals, and dietary supplements.

PharmaResearch Co Headlines

No Headlines